Biotech Values

[mcbio]

…A gold-std. trial in which Peregrine’s Bavituximab is going to AT LEAST DOUBLE **MOS** in 2nd-Line NSCLC = > **MOS** being ULTIMATE ENDPOINT that matters in NSCLC.

This could not be more wrong. MOS doesn't mean much of anything by itself. If PPHM comes back with strong p-values and HR for the bavi arm compared to control, then we may have something to talk about (pending further clarity on the potential concerns pcrutch noted before about possibility that arms may be imbalanced in favor of bavi arm).